Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Rafael Holdings, Inc. (RFL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/30/2021 |
GN
| Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 02/10/2021 |
GN
| LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil® |
| 01/19/2021 |
GN
| Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference |
| 01/13/2021 |
GN
| Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference |
| 12/15/2020 |
GN
| UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) |
| 12/15/2020 |
GN
| Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) |
| 12/01/2020 |
GN
| Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue |
| 11/10/2020 |
GN
| Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer |
| 10/29/2020 |
GN
| FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma |
| 10/20/2020 |
GN
| A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan |
| 08/06/2020 |
GN
| Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®? (devimistat) for Patients with Metastatic Pancreatic Cancer |
| 07/21/2020 |
GN
| Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 05/26/2020 |
GN
| Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program |
| 05/07/2020 |
GN
| Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models |
| 05/05/2020 |
GN
| Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer |
| 04/28/2020 |
GN
| MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia |
| 04/23/2020 |
GN
| Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 03/03/2020 |
GN
| Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer |
| 01/14/2020 |
GN
| Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer |
| 01/13/2020 |
GN
| Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference |
| 12/03/2019 |
GN
| Data on Rafael Pharmaceuticals' CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition |
| 12/03/2019 |
GN
| Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos |
| 12/02/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston |
| 10/30/2019 |
GN
| Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D. |
| 10/24/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer |
| 10/02/2019 |
GN
| Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer |
| 09/19/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 09/16/2019 |
GN
| Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat) |
| 07/30/2019 |
GN
| David A. Polinsky, Esq Appointed to the Board of Directors of Innovative Food Holdings, Inc. |
| 07/18/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer |
| 06/06/2019 |
GN
| Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey |
| 05/16/2019 |
GN
| Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala |
| 03/29/2019 |
GN
| LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019 |
| 03/04/2019 |
GN
| Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer. |
|
|
|